Quetiapine (Seroquel) shows a pattern of behavioral effects similar to the atypical antipsychotics clozapine and olanzapine: Studies with tremulous jaw movements in rats

Psychopharmacology

Volumn 179, Issue 2, 2005, Pages 383-392

  Betz, A ^a   Ishiwari, K ^a   Wisniecki, A ^a   Huyn, N ^a   Salamone, J D ^a  

^a UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

Antipsychotic; Clozapine; Cognex; Extrapyramidal; Motor; Schizophrenia; Tacrine

Indexed keywords

CLOZAPINE; FLUPHENAZINE; HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; PIMOZIDE; QUETIAPINE; RISPERIDONE; TACRINE; THIORIDAZINE;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG POTENCY; JAW; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; TREMOR;

ANIMALS; ANTIPSYCHOTIC AGENTS; BEHAVIOR, ANIMAL; BENZODIAZEPINES; CLOZAPINE; CONDITIONING, OPERANT; DIBENZOTHIAZEPINES; DOSE-RESPONSE RELATIONSHIP, DRUG; JAW; MALE; MOVEMENT; NOOTROPIC AGENTS; RATS; RATS, SPRAGUE-DAWLEY; REINFORCEMENT SCHEDULE; TACRINE;

EID: 17644407316     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-004-2046-9     Document Type: Article

References (90)

1. Alvir JMJ, Liebermail JA, Safferman AZ, Schwimmer JL and Schaaf JA (1993) Clozapine-induced agranulocytosis: incidence and risk factors in the United States. N Engl J Med 329:162-167
2. Arevalo GJ, Gershanik OS (1993) Modulatory effect of clozapine on levodopa response in Parkinson's disease: a preliminary study. Mov Disord 8:349-354
3. Amt J, Skarsfeldt T (1998) Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology 18:63-101
4. Baldessarini RJ, Frankenburg FR (1991) Clozapine: a novel antipsychotic agent. N Engl J Med 324:746-754
5. Baskin P, Salamone JD (1993) Vacuous jaw movements in rat induced by acute reserpine administration: interactions with different doses of apomorphine. Pharmacol Biochem Behav 46:793-797
6. Baskin P, Gianutsos G, Salamone JD (1994) Repeated scopolamine injections sensitize rats to pilocarpine-induced vacuous jaw movements and enhance striatal muscarinic receptor binding. Pharmacol Biochem Behav 49:437-442
7. Beasley CM, Sanger T, Satterlee W, Tollefson GD, Tran PV, Hamilton S (1996) Olanzapine vs. placebo: results of a double-blind, fixed-dose olanzapine trial. Psychopharmacology 124: 159-167
8. Beasley CM, Tollefson GD, Tran PV (1997a) Efficacy of olanzapine: an overview of pivotal clinical trials. J Clin Psychiatry 58:s7-s12
9. Beasley CM, Tollefson GD, Tran PV (1997b) Safety of olanzapine. J Clin Psychiatry 58:s13-s17
10. Bernardi F, Del Zompo M (1990) Clozapine in idiopathic Parkinson's disease. Neurology 40:1151
11. Broderick PA, Rahni DN, Zhou Y (2003) Acute and subacute effects of risperidone and cocaine on accumbens dopamine and serotonin release using in vivo microvoltammetry on line with open-field behavior. NeuroPsychopharm Biol Psychiatry 27:1037-1054
12. Bymaster FP, Hemrick-Lueke SK, Pery KW, Fuller RW (1996) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin, alpha1-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87-94
13. Bymaster FP, Rasmussen K, Calligaro DO, Nelson DL, DeLapp NW, Wong DT, Moore NA (1997) In vitro and in vivo biochemistry of olanzapine: a novel, atypical antipsychotic drug. J Clin Psychiatry 58:s28-s36
14. Carlson BB, Trevitt JT, Salamone JD (2000) Effects of H1 antagonists on cholinomimetic-induced tremulous jaw movements: studies of diphenhydramine, doxepin, and mepyramine. Pharmacol Biochem Behav 65:683-689
15. Carlson BB, Wisniecki A, Salamone JD (2003) Local injections of the 5-hydroxytryptamine antagonist mianserin into substantia nigra pars reticulata block tremulous jaw movements in rats: studies with a putative model of Parkinsonian tremor. Psychopharmacology 165:229-237
16. Casey DE (1997) The relationship of pharmacology to side effects. J Clin Psychiatry 58:s55-s62
17. Chesler EJ, Salamone JD (1996) Effects of acute and repeated clozapine injections on cholinomimetic-induced vacuous jaw movements. Pharmacol Biochem Behav 54:619-624
18. Collins P, Broekkamp CLE, Jenner P, Marsden CD (1993) Electromyographic differentiation of the components of perioral movements induced by SKF 38393 and physostigmine in the rat. Psychopharmacology 112:428-436
19. Correa M, Wisniecki A, Betz A, Dobson DR, O'Neill MF, O'Neill MJ, Salamone JD (2004) The adenosine A2A antagonist KF17837 reverses the locomotor suppression and tremulous jaw movements induced by haloperidol in rats: possible relevance to parkinsonism. Behav Brain Res 148:47-54
20. Cousins MS, Salamone JD (1998) Behavioral and electromyographic characterization of the local frequency of tacrine-induced tremulous jaw movements. Physiol Behav 64:153-158
21. Cousins MS, Carriero DL, Salamone JD (1997) Tremulous jaw movements induced by the acetylcholinesterase inhibitor tacrine: effects of antiparkinsonian drugs. Eur J Pharmacol 322:137-145
22. De Souza IEJ, Dawson NM, Clifford JJ, Waddington JL, Meredith E (2003) Relationship of orofacial movements to behavioural repertoire as assessed topographically over the course of 6-month haloperidol treatment followed by 4-month withdrawal. Psychopharmacology 169:28-34
23. Duvoisin RC (1967) Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol 17:124-136
24. Egan MF, Hurd Y, Ferguson J, Bachus SE, Hamid EH, Hyde TM (1996) Pharmacological and neurochemical differences between acute and tardive vacuous chewing movements induced by haloperidol. Psychopharmacology 127:337-345
25. Factor SA and Friedman JH (1997) The emerging role of clozapine in the treatment of movement disorders. Mov Disord 12:483-496
26. Fernandez HH, Friedman JH, Jacques C, Rosenfeld M (1999) Quetiapine for the treatment of drug-induced psychosis in Parkinson's disease. Mov Disord 14:484-487
27. Fernandez HH, Trieschmann ME, Friedman JH (2003) Treatment of psychosis in Parkinson's disease: safety considerations. Drug Saf 26:643-659
28. Finn M, Jassen A, Baskin P (1997) Tremulous characteristics of the vacuous jaw movements induced by pilocarpine and ventrolateral striatal dopamine depletions. Pharmacol Biochem Behav 57:243-249
29. Fisher PA, Baas H, Hefner R (1990) Treatment of parkinsonian tremor with clozapine. J Neurotrans 2:233-238
30. Friedman JH, Lannon MC (1990) Clozapine-responsive tremor in Parkinson's disease. Mov Disord 5:225-229
31. Fulton B, Goa K (1997) Olanzapine - A review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 53:281-298
32. Gao XM, Sakai K, Tamminga CA (1998) Chronic olanzapine or sertindole treatment results in reduced oral chewing movements in rats compared to haloperidol. Neuropsychopharmacology 19:428-433
33. Gunne LM, Andersson U, Bondesson U, Johansson P (1986) Spontaneous chewing movements in rats during acute and chronic antipsychotic drug administration. Pharmacol Biochem Behav 25:897-901
34. Harbaugh RE, Roberts DW, Coombs DW, Saunders RL, Reeder TM (1984) Preliminary report: intracranial cholinergic drug infusion in patients with Alzheimer's disease. Neurosurgery 15: 514-518
35. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitigawa H, Burris KD, Altar CA, Nabeshima T (2004) Mechanism of action of aripiprazole predicts clinical efficacy and favourable side effect profile. J Psychopharmacol 18:375-383
36. Hoffman DC, Donovan H (1995) Catalepsy as a rodent model for detecting antipsychotic drugs with extrapyramidal side effect liability. Psychopharmacology 120:128-133
37. Ishiwari K, Betz A, Weber S, Felsted J, Salamone JD (2005) Validation of the tremulous jaw movement model for assessment of the motor effects of typical and atypical antipychotics: effects of pimozide (orap) in rats. Pharmacol Biochem Behav (in press)
38. Jicha G, Salamone JD (1991) Vacuous jaw movements and feeding deficits in rats with ventrolateral striatal dopamine depletion: possible relation to Parkinsonian symptoms. J Neurosci 11: 3822-3829
39. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic. Arch Gen Psychiatry 45: 789-796
40. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine D2 receptor explain the action of atypical antipsychotics? A new hypothesis. Am J Psychiatry 158:360-369
41. Kelley AE, Bakshi VP, Delfs JM, Lang CG (1989) Cholinergic stimulation of the ventrolateral striatum elicits mouth movements in rats: pharmacological and regional specificity. Psychopharmacology 99:542-549
42. Keppel G (1982) Design and analysis: a researchers handbook. Prentice Hall, Englewood
43. Komada R, Morita S, Miwa H, Kondo T (2003) Three patients with Parkinson's Disease whose therapeutic levels were successfully improved after administration of quetiapine for suppression of psychosis. No To Shinkei 55:413-417
44. Marchese G, Casu MA, Bartholini F, Ruiu S, Saba P (2002) Subchronic treatment with classical but not atypical antipsychotics produces morphological changes in rat nigro-striatal dopaminergic neurons directly related to 'early onset' vacuous chewing. Eur J Neurosci 15:1187-1196
45. Marchese G, Bartholini F, Casu MA, Ruiu S, Casti P, Congeddu E, Tambaro S, Pani L (2004) Haloperidol versus risperidone on rat "early onset" vacuous chewing. Behav Brain Res 149:9-16
46. Marsden CD, Tarsy D, Baldessarini RJ (1975) Spontaneous and drug-induced movement disorders in psychotic patients. In: Bendon DF, Blumer D (eds) Psychiatric aspects of neurological disease. New York, pp 219-266
47. Mayorga AJ, Carriero DL, Cousins MS, Gianutsos G, Salamone JD (1997) Tremulous jaw movements produced by acute tacrine administration: Possible relation to parkinsonian side effects. Pharmacol Biochem Behav 56:273-279
48. Mayorga AJ, Cousins MS, Trevitt JT, Conlan A, Gianutsos G, Salamone JD (1999) Characterization of the muscarinic receptor subtype mediating pilocarpine-induced tremulous jaw movements in rats. Eur J Pharmacol 364:7-11
49. McEvoy JP (1983) The clinical use of anticholinergic drugs as treatment for extrapyramidal side effects of neuroleptic drugs. J Clin Psychopharmacol 3:288-301
50. Meltzer HY (1989) Clinical studies on the mechanism of action of clozapine: the dopamine-serotonin hypothesis of schizophrenia. Psychopharmacology 99:s18-s27
51. Miller RJ, Hiley CR (1974) Anti-muscarinic properties of neuroleptics and drug-induced parkinsonism. Nature 248:596-597
52. Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994) Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Compr Psychiatry 35:8-15
53. Moore NA, Tye NC, Axton MS, Risius FC (1992) The behavioral pharmacology of olanzapine, a novel "atypical" antipsychotic agent. J Pharmacol Exp Ther 262:545-551
54. Moore NA, Leander JD, Benvenga MJ, Gleason SD, Shannon H (1997) Behavioral pharmacology of olanzapine: a novel antipsychotic drug. J Clin Psychiatry 58:s37-s44
55. Noring U, Povlesen UJ, Casey DE, Gerlach J (1984) Effect of a cholinomimetic drug (RS 86) in tardive dyskinesia and drug-related parkinsonism. Psychopharmacology 84:569-571
56. Pakkenberg H, Pakkenberg B (1986) Clozapine in the treatment of tremor. Acta Neurol Scand 73:295-297
57. Pilowski LS, Busatto GF, Taylor M, Costa DC, Sharma T, Sigmundson T, Ell PJ, Nohira V and Kerwin RW (1996) Dopamine D2 receptor occupancy in vivo by the novel atypical antipsychotic olanzapine - a 123I IBZM single photome emission tomography study. Psychopharmacology 124:148-153
58. Richelson E, Souder T (2000) Binding of antipsychotic drugs to human brain receptors focus on newer generation compounds. Life Sci 68:29-39
59. Roth BL, Tandra S, Burgess LH, Sibley DR, Meltzer HY (1995) D4 dopamine receptor binding affinity does not distinguish between typical and atypical antipsychotic drugs. Psychopharmacology 120:365-368
60. Rupniak NMJ, Jenner P, Marsden CD (1983) Cholinergic modulation of perioral behavior induced by chronic neuroleptic administration to rats. Psychopharmacology 79:226-230
61. Rupniak NMJ, Jenner P, Marsden CD (1985) Pharmacological characterization of spontaneous or drug-induced purposeless chewing movements in rats. Psychopharmacology 85:71-79
62. Safferman A, Lieberman JA, Kane JM, Szymanski S, Kinon B (1991) Update on the clinical efficacy of clozapine. Schizophr Bull 17:247-261
63. Salamone JD, Baskin PB (1996) Vacuous jaw movements induced by reserpine and low-dose apomorphine: possible model of parkinsonian tremor. Pharmacol Biochem Behav 53:179-183
64. Salamone JD, Lalies MD, Channell SL, Iversen SD (1986) Behavioral and pharmacological characterization of the mouth movements induced by muscarinic agonists in the rat. Psychopharmacology 88:467-471
65. Salamone JD, Johnson CJ, McCullough LD, Steinpreis RE (1990) Lateral striatal cholinergic mechanisms involved in oral motor activities in the rat. Psychopharmacology 102:529-534
66. Salamone JD, Cousins MS, Maio C, Champion M, Turski T, Kovach J (1996) Different behavioral effects of haloperidol, clozapine and thioridazine in an instrumental lever pressing/ feeding procedure. Psychopharmacology 125:105-112
67. Salamone JD, Mayorga AJ, Trevitt JT, Cousins MS, Conlan A, Nawab A (1998) Tremulous jaw movements in rats: a model of parkinsonian tremor. Prog Neurobiol 56:591-611
68. Salamone JD, Correa M, Carlson BB, Wisniecki A, Mayorga AJ, Nisenbaum E, Nisenbaum L, Felder C (2001) Neostriatal muscarinic receptor subtypes involved in the generation of tremulous jaw movements in rodents implications for cholinergic involvement in parkinsonism. Life Sci 68:2579-2584
69. Salamone JD, Carlson BB, Rios C, Lentini E, Correa M, Wisniecki A, Betz A (2005) Dopamine agonists suppress cholinomimetic-induced tremulous jaw movements in an animal model of parkinsonism: tremorolytic effects of pergolide, ropinirole and CY 208-243. Behav Brain Res 156:173-179
70. Schotte A, Janssen PFM, Gommeren W, Luyten WHML, Van Gompel P, Lesage AS, De Moore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: In vitro and in vivo receptor binding. Psychopharmacology 124:57-73
71. Seeman P, Corvett R, Van Tol HHM (1997) Atypical neuroleptics have low affinity for dopamine D2 receptors or are selective for D4 receptors. Neuropsychopharmacology 16:93-110
72. Snyder SH, Banerjee SP, Yamamura HI, Greenberg D (1974) Drugs, neurotransmitters and schizophrenia. Science 184:1243-1253
73. Stanford JA, Fowler SC (1997) Similarities and differences between the subchronic and withdrawal effects of clozapine on forelimb force steadiness. Psychopharmacology 132:408-414
74. Steinpreis RE, Salamone JD (1993) The effects of acute haloperidol and reserpine administration on vacuous jaw movements in three different age groups of rats. Pharmacol Biochem Behav 46:405-409
75. Steinpreis RE, Baskin PP, Salamone JD (1993) Vacuous jaw movements induced by sub-chronic administration of haloperidol: Interactions with scopolamine. Psychopharmacology 111: 99-105
76. Steinpreis RE, Parret F, Summ R, Panos JJ (1997) Effects of clozapine and haloperidol on baseline levels of vacuous jaw movements in aged rats. Behav Brain Res 86:165-169
77. Stewart B, Rose S, Jenner P, Marsden CD (1987) Pilocarpine-induced puposeless chewing behavior in rats is dependent on intact stores of 5-HT. Eur J Pharmacol 142:173-176
78. Stewart BR, Jenner P, Marsden CD (1988) The pharmacological characterization of pilocarpine-induced chewing in the rat. Psychopharmacology 97:228-234
79. Tandon R (2003) Improvement without impairment: a review of clinical data for quetiapine in the treatment of schizophrenia. J Clin Psychopharmacol 23(Suppl 1):S15-S20
80. Tarsy D (1983) Neuroleptic-induced extrapyramidal reactions: Classification, description and diagnosis. Clin Neuropsychopharm 6:s9-s26
81. Tarsy D, Baldessarini RJ, Tarazi FI (2002) Effects of newer antipsychotics on extrapyramidal function. CNS Drugs 16:23-45
82. Tollefson GD, Beasley CM, Tran PV, Street JS, Krueger JA, Tamura RN, Graffeo KA, Thieme ME (1997) Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial. Am J Psychiatry 154:457-465
83. Trevitt JT, Lyons M, Aberman J, Carriero D, Finn M, Salamone JD (1997) Effects of clozapine, thioridazine, risperidone and haloperidol on behavioral tests related to extrapyramidal motor function. Psychopharmacology 132:74-81
84. Trevitt JT, Atherton LA, Aberman J, Salamone JD (1998) Effects of subchronic administration of clozapine, thioridazine and haloperidol on tests related to extrapyramidal motor function. Psychopharmacology 137:61-66
85. Trevitt JT, Carlson BB, Salamone JD (1999) Behavioral assessment of atypical antipsychotics in rats: studies of the effects of olanzapine (Zyprexa). Psychopharmacology 145:309-316
86. Turrone P, Remington G, Kapur S, Nobrega J (2003) The relationship between dopamine D2 receptor occupancy and the vacuous chewing movement syndrome in rats. Psychopharmacology 165:166-171
87. Weiss KJ, Ciraulo DA, Shader RI (1980) Physostigmine test in the rabbit syndrome and tardive dyskinesia. Am J Psychiatry 137:627-628
88. Wijnen HH, van der Heijden FM, van Schendel FME, Tuinier S, Verhoeven WMA (2003) Quetiapine in the elderly with parkinsonism and psychosis. Eur Psychiatry 18:372-373
89. Wiley JL, Compton AD, Porter JH (1994) Differential effects of clozapine and pimozide on fixed-ratio responding during repeated dosing. Pharmacol Biochem Behav 48:253-257
90. Wisniecki A, Correa M, Arizzi MN, Ishiwari K, Salamone JD (2003) Motor effects of GABA(A) antagonism in globus pallidus: studies of locomotion and tremulous jaw movements in rats. Psychopharmacology 170:140-149